AMGN/NVS’ CGRP/migraine drug, Erenumab hits primary endpoint in second phase-3 trial: http://finance.yahoo.com/news/amgen-announces-erenumab-significantly-reduces-213000859.html Positive data from the first Erenumab phase-3 trial were reported in Sep 2016 (#msg-125455190).